Gene Therapy Market by Type (Gene silencing), Vector (Viral (Retroviral, AAV), Non-viral (Oligonucleotide)), Gene Type (Receptors, Cytokine), Therapeutic Area (Oncology, Neurology), Delivery Method (In-Vivo, Ex-Vivo), RoA (IV) - Global Forecast to 2032

1 INTRODUCTION 41 1.1 STUDY OBJECTIVES 41 1.2 MARKET DEFINITION 41 1.3 STUDY SCOPE 42 1.3.1 MARKETS COVERED & REGIONAL SEGMENTATION 42 1.3.2 INCLUSIONS & EXCLUSIONS 43 1.3.3 YEARS CONSIDERED 44 1.3.4 CURRENCY CONSIDERED 44 1.4 STAKEHOLDERS 44 1.5 SUMMARY OF CHANGES 45 2 RESEARCH METHODOLOGY 46 2.1 RESEARCH DATA 46 2.1.1 SECONDARY RESEARCH 47 2.1.1.1 Key data from secondary sources 48 2.1.2 PRIMARY RESEARCH 48 2.1.2.1 Insights of primary experts 50 2.2 MARKET SIZE ESTIMATION 51 2.2.1 GLOBAL MARKET ESTIMATION 51 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION 53 2.3 MARKET GROWTH RATE PROJECTIONS 54 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 56 2.5 RESEARCH ASSUMPTIONS 57 2.6 RESEARCH LIMITATIONS 58 2.7 RISK ANALYSIS 58 3 EXECUTIVE SUMMARY 59 4 PREMIUM INSIGHTS 64 4.1 GENE THERAPY MARKET OVERVIEW 64 4.2 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE & COUNTRY (2024) 65 4.3 GENE THERAPY MARKET SHARE, BY END USER, 2024 VS 2032 66 4.4 GENE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 66   5 MARKET OVERVIEW 67 5.1 INTRODUCTION 67 5.2 MARKET DYNAMICS 67 5.2.1 DRIVERS 68 5.2.1.1 Growing demand for curative therapies for genetic disorders, rare diseases, and cancers 68 5.2.1.2 Increasing investments in gene therapy research 70 5.2.1.3 Technological advancements 71 5.2.1.4 Robust clinical trial pipeline for gene therapy 72 5.2.2 RESTRAINTS 73 5.2.2.1 High cost of gene therapy products 73 5.2.2.2 Complex regulatory frameworks and ethical concerns regarding genetic modifications 73 5.2.2.3 Limited manufacturing scalability 74 5.2.3 OPPORTUNITIES 74 5.2.3.1 Expansion into rare diseases and unmet needs 74 5.2.3.2 Increasing focus on precision medicine 75 5.2.3.3 Advancements in gene therapy delivery technologies 76 5.2.4 CHALLENGES 76 5.2.4.1 Complex commercial manufacturing and scaling process 76 5.2.4.2 Short shelf life and supply chain challenges 77 5.2.4.3 Lack of reimbursement 77 5.3 TECHNOLOGY ANALYSIS 78 5.3.1 KEY TECHNOLOGIES 78 5.3.1.1 CRISPR-Cas9 78 5.3.1.2 RNA interference 78 5.3.1.3 Viral vectors 78 5.3.2 COMPLEMENTARY TECHNOLOGIES 79 5.3.2.1 Stem cell therapy 79 5.3.2.2 Omics technologies 79 5.3.3 ADJACENT TECHNOLOGIES 79 5.3.3.1 Nanoparticles 79 5.4 VALUE CHAIN ANALYSIS 80 5.5 SUPPLY CHAIN ANALYSIS 81 5.5.1 PROMINENT COMPANIES 81 5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES 81 5.5.3 END USERS 81 5.5.4 INVESTORS, VENTURE CAPITALISTS, AND FUNDING BODIES 81 5.5.5 REGULATORY BODIES 81 5.6 ECOSYSTEM ANALYSIS 82 5.7 PATENT ANALYSIS 85 5.8 PIPELINE ANALYSIS 88 5.9 REGULATORY LANDSCAPE 89 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION 89 5.9.2 REGULATORY FRAMEWORK 91 5.9.3 REIMBURSEMENT SCENARIO 92 5.10 PRICING ANALYSIS 94 5.10.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 94 5.10.2 AVERAGE SELLING PRICE TREND, BY REGION 96 5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 98 5.12 KEY CONFERENCES & EVENTS, 2025–2026 99 5.13 PORTER’S FIVE FORCES ANALYSIS 100 5.13.1 THREAT OF NEW ENTRANTS 101 5.13.2 THREAT OF SUBSTITUTES 101 5.13.3 BARGAINING POWER OF SUPPLIERS 101 5.13.4 BARGAINING POWER OF BUYERS 102 5.13.5 INTENSITY OF COMPETITIVE RIVALRY 102 5.14 KEY STAKEHOLDERS & BUYING CRITERIA 102 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 102 5.14.2 BUYING CRITERIA 104 5.15 INVESTMENT & FUNDING SCENARIO 105 5.16 IMPACT OF AI ON GENE THERAPY MARKET 106 6 GENE THERAPY MARKET, BY THERAPY TYPE 108 6.1 INTRODUCTION 109 6.2 GENE SILENCING THERAPY 109 6.2.1 FLEXIBILITY AND PRECISION OF GENE SILENCING THERAPIES TO SUPPORT GROWTH 109 6.3 CELL REPLACEMENT THERAPY 113 6.3.1 LONG-TERM EFFECT OF THERAPY TO SUPPORT GROWTH IN ADOPTION 113 6.4 GENE AUGMENTATION THERAPY 116 6.4.1 EFFECTIVENESS AGAINST MONOGENIC DISORDERS TO DRIVE MARKET 116 6.5 OTHER THERAPIES 120 7 GENE THERAPY MARKET, BY VECTOR 124 7.1 INTRODUCTION 125 7.2 VIRAL VECTORS 125 7.2.1 RETROVIRAL VECTORS 129 7.2.1.1 Advantages of retroviral vectors to support market growth 129 7.2.1.2 Gamma-retroviral vectors 132 7.2.1.2.1 Availability of gamma-retroviral vectors to support market growth 132 7.2.1.3 Lentiviral vectors 135 7.2.1.3.1 North America to dominate lentiviral vectors market 135 7.2.2 AAV VECTORS 138 7.2.2.1 Focus of clinical pipeline on adeno-associated viral vectors to drive growth 138 7.2.3 OTHER VIRAL VECTORS 141 7.3 NON-VIRAL VECTORS 144 7.3.1 OLIGONUCLEOTIDE VECTORS 148 7.3.1.1 Oligonucleotides to account for largest share of non-viral vectors market 148 7.3.2 OTHER NON-VIRAL VECTORS 151 8 GENE THERAPY MARKET, BY GENE TYPE 154 8.1 INTRODUCTION 155 8.2 DEFICIENCY 155 8.2.1 TECHNOLOGICAL ADVANCEMENT IN GENE THERAPIES TO BOOST GROWTH 155 8.3 RECEPTOR 159 8.3.1 INCREASING DEMAND FOR DEVELOPING RECEPTOR-BASED GENE THERAPY TO SUPPORT MARKET GROWTH 159 8.4 ANTIGEN 162 8.4.1 INCREASING DEMAND FOR TARGETED THERAPIES TO PROPEL GROWTH 162 8.5 CYTOKINE 165 8.5.1 RISING R&D TO SUPPORT MARKET GROWTH 165 8.6 TUMOR SUPPRESSOR 169 8.6.1 RISING PREVALENCE OF CANCER TO PROPEL MARKET GROWTH 169 8.7 OTHER GENES 172 9 GENE THERAPY MARKET, BY THERAPEUTIC AREA 176 9.1 INTRODUCTION 177 9.2 NEUROLOGY 177 9.2.1 ENHANCED DELIVERY METHODS AND ADVANCEMENTS IN GENE EDITING TECHNOLOGIES TO BOOST MARKET GROWTH 177 9.3 ONCOLOGY 181 9.3.1 RISING BURDEN OF CANCER TO SUPPORT MARKET GROWTH 181 9.4 HEMATOLOGY 184 9.4.1 INCREASING PREVALENCE OF GENETIC BLOOD DISORDERS TO BOOST MARKET GROWTH 184 9.5 OTHER THERAPEUTIC AREAS 188 10 GENE THERAPY MARKET, BY DELIVERY METHOD 191 10.1 INTRODUCTION 192 10.2 IN VIVO DELIVERY 192 10.2.1 IN VIVO DELIVERY METHOD TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023 192   10.3 EX VIVO DELIVERY 196 10.3.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO SUPPORT MARKET GROWTH 196 11 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION 200 11.1 INTRODUCTION 201 11.2 INTRAVENOUS ROUTE 201 11.2.1 HIGH EFFECTIVENESS AND LARGE SHARE OF INTRAVENOUS PRODUCTS TO SUPPORT MARKET GROWTH 201 11.3 SUBCUTANEOUS ROUTE 205 11.3.1 DEVELOPMENT OF IMPROVED DELIVERY DEVICES TO SUPPORT MARKET GROWTH 205 11.4 OTHER ROUTES 208 12 GENE THERAPY MARKET, BY END USER 212 12.1 INTRODUCTION 213 12.2 HOSPITALS 213 12.2.1 GROWING DEMAND FOR ADVANCED THERAPIES TO BOOST MARKET 213 12.3 SPECIALTY CENTERS 217 12.3.1 ADVANCEMENTS IN GENE THERAPY TECHNOLOGIES TO SUPPORT MARKET GROWTH 217 12.4 OTHER END USERS 220 13 GENE THERAPY MARKET, BY REGION 224 13.1 INTRODUCTION 225 13.2 NORTH AMERICA 225 13.2.1 NORTH AMERICA: MACROECONOMIC ANALYSIS 226 13.2.2 US 231 13.2.2.1 US to dominate North American market during forecast period 231 13.2.3 CANADA 236 13.2.3.1 Government support for expanding manufacturing facilities to propel market growth 236 13.3 EUROPE 239 13.3.1 EUROPE: MACROECONOMIC ANALYSIS 239 13.3.2 GERMANY 245 13.3.2.1 Growing pharmaceutical R&D and manufacturing to drive market 245 13.3.3 UK 249 13.3.3.1 Strong government support to propel market growth 249 13.3.4 FRANCE 253 13.3.4.1 Government investment in pharmaceutical industry to drive growth 253 13.3.5 ITALY 257 13.3.5.1 Initiatives for gene therapy development to drive growth 257 13.3.6 SPAIN 260 13.3.6.1 Expansion of biomanufacturing facilities to support market growth 260 13.3.7 SWITZERLAND 264 13.3.7.1 Presence of key pharmaceutical and biopharmaceutical companies to support market growth 264 13.3.8 NETHERLANDS 268 13.3.8.1 Growing awareness and strong focus on pharmaceutical R&D to support market growth 268 13.3.9 REST OF EUROPE 271 13.4 ASIA PACIFIC 275 13.4.1 ASIA PACIFIC: MACROECONOMIC ANALYSIS 275 13.4.2 CHINA 280 13.4.2.1 China to dominate Asia Pacific market during forecast period 280 13.4.3 JAPAN 284 13.4.3.1 Increasing initiatives supporting gene therapy adoption to propel market growth 284 13.4.4 INDIA 288 13.4.4.1 Favorable scenario for foreign direct investment to favor market growth 288 13.4.5 AUSTRALIA 292 13.4.5.1 Increasing demand for innovative therapies to propel market 292 13.4.6 SOUTH KOREA 296 13.4.6.1 Increased export of drugs to support market growth 296 13.4.7 THAILAND 299 13.4.7.1 Favorable government policies to propel adoption of advanced therapies 299 13.4.8 REST OF ASIA PACIFIC 303 13.5 LATIN AMERICA 307 13.5.1 LATIN AMERICA: MACROECONOMIC ANALYSIS 307 13.5.2 BRAZIL 312 13.5.2.1 Brazil to dominate LATAM market during forecast period 312 13.5.3 MEXICO 315 13.5.3.1 Rising demand for chronic disease treatment to support market growth 315 13.5.4 REST OF LATIN AMERICA 319 13.6 MIDDLE EAST 323 13.6.1 MIDDLE EAST: MACROECONOMIC ANALYSIS 323 13.6.2 GCC COUNTRIES 328 13.6.2.1 Saudi Arabia 332 13.6.2.1.1 Growing healthcare expenditure to boost market growth 332 13.6.2.2 UAE 336 13.6.2.2.1 Growing focus on genetic medicine development projects to drive market 336 13.6.2.3 Rest of GCC Countries 339 13.6.3 REST OF MIDDLE EAST 343   13.7 AFRICA 347 13.7.1 HIGH GROWTH POTENTIAL OF AFRICAN MARKETS TO ATTRACT KEY PLAYERS 347 13.7.2 AFRICA: MACROECONOMIC ANALYSIS 347 14 COMPETITIVE LANDSCAPE 352 14.1 OVERVIEW 352 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022–2024 352 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENE THERAPY MARKET, 2022−2024 352 14.3 REVENUE ANALYSIS, 2021–2023 353 14.4 MARKET SHARE ANALYSIS, 2023 354 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 356 14.5.1 STARS 357 14.5.2 EMERGING LEADERS 357 14.5.3 PERVASIVE PLAYERS 357 14.5.4 PARTICIPANTS 357 14.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2023 359 14.5.5.1 Company footprint 359 14.5.5.2 Region footprint 360 14.5.5.3 Therapy type footprint 361 14.5.5.4 Therapeutic area footprint 362 14.5.5.5 Route of administration footprint 363 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 364 14.6.1 PROGRESSIVE COMPANIES 364 14.6.2 RESPONSIVE COMPANIES 364 14.6.3 DYNAMIC COMPANIES 364 14.6.4 STARTING BLOCKS 364 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 366 14.6.5.1 Detailed list of key startups/SMEs 366 14.6.5.2 Competitive benchmarking of key startups/SMEs 367 14.7 VALUATION & FINANCIAL METRICS 368 14.7.1 FINANCIAL METRICS 368 14.7.2 COMPANY VALUATION 368 14.8 BRAND/PRODUCT COMPARISON 369 14.9 COMPETITIVE SCENARIO 370 14.9.1 PRODUCT APPROVALS 370 14.9.2 DEALS 371 14.9.3 EXPANSIONS 373   15 COMPANY PROFILES 374 15.1 INTRODUCTION 374 15.2 KEY PLAYERS 374 15.2.1 BIOGEN INC. 374 15.2.1.1 Business overview 374 15.2.1.2 Products offered 375 15.2.1.3 Recent developments 376 15.2.1.3.1 Deals 376 15.2.1.4 MnM view 376 15.2.1.4.1 Key strengths 376 15.2.1.4.2 Strategic choices 377 15.2.1.4.3 Weaknesses and competitive threats 377 15.2.2 NOVARTIS AG 378 15.2.2.1 Business overview 378 15.2.2.2 Products offered 379 15.2.2.3 Recent developments 380 15.2.2.3.1 Deals 380 15.2.2.3.2 Expansions 380 15.2.2.3.3 Other developments 381 15.2.2.4 MnM view 381 15.2.2.4.1 Key strengths 381 15.2.2.4.2 Strategic choices 381 15.2.2.4.3 Weaknesses and competitive threats 381 15.2.3 ALNYLAM PHARMACEUTICALS, INC. 382 15.2.3.1 Business overview 382 15.2.3.2 Products offered 383 15.2.3.3 Recent developments 384 15.2.3.3.1 Product approvals 384 15.2.3.3.2 Deals 384 15.2.3.3.3 Other developments 385 15.2.3.4 MnM view 385 15.2.3.4.1 Key strengths 385 15.2.3.4.2 Strategic choices 385 15.2.3.4.3 Weaknesses and competitive threats 385 15.2.4 SAREPTA THERAPEUTICS, INC. 386 15.2.4.1 Business overview 386 15.2.4.2 Products offered 387 15.2.4.3 Recent developments 388 15.2.4.3.1 Product approvals 388 15.2.4.3.2 Deals 388 15.2.4.4 MnM view 389 15.2.4.4.1 Key strengths 389 15.2.4.4.2 Strategic choices 389 15.2.4.4.3 Weaknesses and competitive threats 389 15.2.5 JAZZ PHARMACEUTICALS PLC 390 15.2.5.1 Business overview 390 15.2.5.2 Products offered 391 15.2.5.3 Recent developments 392 15.2.5.3.1 Expansions 392 15.2.5.4 MnM view 392 15.2.5.4.1 Key strengths 392 15.2.5.4.2 Strategic choices 392 15.2.5.4.3 Weaknesses and competitive threats 392 15.2.6 FERRING B.V. 393 15.2.6.1 Business overview 393 15.2.6.2 Products offered 394 15.2.6.3 Recent developments 394 15.2.6.3.1 Product approvals 394 15.2.6.3.2 Deals 394 15.2.6.3.3 Expansions 395 15.2.7 PFIZER INC. 396 15.2.7.1 Business overview 396 15.2.7.2 Products offered 397 15.2.7.3 Recent developments 398 15.2.7.3.1 Product approvals 398 15.2.7.3.2 Deals 398 15.2.8 AMGEN, INC. 399 15.2.8.1 Business overview 399 15.2.8.2 Products offered 400 15.2.8.3 Recent developments 400 15.2.8.3.1 Deals 400 15.2.8.3.2 Expansions 400 15.2.9 JOHNSON & JOHNSON SERVICES, INC. 401 15.2.9.1 Business overview 401 15.2.9.2 Products offered 402 15.2.9.3 Recent developments 402 15.2.9.3.1 Deals 402 15.2.9.3.2 Other developments 403 15.2.10 DAIICHI SANKYO COMPANY, LIMITED. 404 15.2.10.1 Business overview 404 15.2.10.2 Products offered 405   15.2.11 BIOMARIN PHARMACEUTICAL INC. 406 15.2.11.1 Business overview 406 15.2.11.2 Products offered 407 15.2.11.3 Recent developments 407 15.2.11.3.1 Product approvals 407 15.2.11.3.2 Expansions 408 15.2.12 KYOWA KIRIN CO., LTD. 409 15.2.12.1 Business overview 409 15.2.12.2 Products offered 410 15.2.12.3 Recent developments 411 15.2.12.3.1 Product approvals 411 15.2.12.3.2 Deals 411 15.2.13 NIPPON SHINYAKU CO., LTD. 412 15.2.13.1 Business overview 412 15.2.13.2 Products offered 413 15.2.13.3 Recent developments 414 15.2.13.3.1 Deals 414 15.2.14 PTC THERAPEUTICS 415 15.2.14.1 Business overview 415 15.2.14.2 Products offered 416 15.2.14.3 Recent developments 416 15.2.14.3.1 Product approvals 416 15.2.15 UNIQURE NV. 417 15.2.15.1 Business overview 417 15.2.15.2 Products offered 418 15.2.15.3 Recent developments 418 15.2.15.3.1 Deals 418 15.3 OTHER PLAYERS 419 15.3.1 JUVENTAS CELL THERAPY LTD. 419 15.3.2 CRISPR THERAPEUTICS 419 15.3.3 BLUEBIRD BIO, INC. 420 15.3.4 KRYSTAL BIOTECH, INC. 421 15.3.5 SHANGHAI SUNWAY BIOTECH CO., LTD. 421 15.3.6 JW (CAYMAN) THERAPEUTICS CO. LTD 422 15.3.7 IASO BIOTECHNOLOGY 422 15.3.8 CARSGEN THERAPEUTICS HOLDINGS LIMITED 423 15.3.9 ADAPTIMMUNE 423 15.3.10 SIBIONO GENETECH CO. LTD. 424 15.3.11 ULTRAGENYX PHARMACEUTICAL INC. 424   16 APPENDIX 425 16.1 DISCUSSION GUIDE 425 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 430 16.3 CUSTOMIZATION OPTIONS 432 16.4 RELATED REPORTS 432 16.5 AUTHOR DETAILS 433

TABLE 1 GENE THERAPY MARKET: INCLUSIONS & EXCLUSIONS 43 TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 55 TABLE 3 GENE THERAPY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 68 TABLE 4 GENE THERAPY MARKET: KEY PRODUCT APPROVALS, 2022–2024 69 TABLE 5 GENE THERAPY MARKET: INVESTMENTS AND FINANCING BY STARTUPS, 2024 70 TABLE 6 GENE THERAPY MARKET: LIST OF ADVANCED PLATFORMS LAUNCHED IN 2022–2024 71 TABLE 7 NUMBER OF CLINICAL TRIALS FOR GENE THERAPY DRUGS, 2024 72 TABLE 8 COST OF KEY GENE THERAPY PRODUCTS, 2024 73 TABLE 9 GENE THERAPY MARKET: RAW MATERIAL VENDORS 83 TABLE 10 GENE THERAPY MARKET: PRODUCT VENDORS 83 TABLE 11 GENE THERAPY MARKET: ROLE OF END USERS 84 TABLE 12 GENE THERAPY MARKET: REGULATORY BODIES 84 TABLE 13 GENE THERAPY MARKET: INDICATIVE LIST OF PATENTS, 2023–2024 87 TABLE 14 GENE THERAPY PRODUCTS IN CLINICAL PIPELINE 88 TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89 TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90 TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90 TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91 TABLE 19 COUNTRY-WISE REGULATORY SCENARIO FOR GENE THERAPY PRODUCTS 91 TABLE 20 US: REIMBURSEMENT CODES FOR GENE THERAPY PRODUCTS 93 TABLE 21 EUROPE: REIMBURSEMENT SCENARIO FOR GENE THERAPY PRODUCTS, BY COUNTRY 94 TABLE 22 AVERAGE SELLING PRICE TREND OF GENE THERAPIES, BY KEY PLAYER, 2022–2024 (USD) 95 TABLE 23 AVERAGE SELLING PRICE TREND OF GENE THERAPIES, BY REGION, 2022–2024 (USD) 97 TABLE 24 GENE THERAPY MARKET: KEY CONFERENCES & EVENTS, 2025–2026 99 TABLE 25 GENE THERAPY MARKET: IMPACT OF PORTER’S FIVE FORCES 100 TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%) 103 TABLE 27 KEY BUYING CRITERIA FOR GENE THERAPY PRODUCTS, BY END USER 104 TABLE 28 GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 109 TABLE 29 GENE SILENCING THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 110 TABLE 30 NORTH AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 110 TABLE 31 EUROPE: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 111 TABLE 32 ASIA PACIFIC: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 111 TABLE 33 LATIN AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 112 TABLE 34 MIDDLE EAST: GENE SILENCING THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 112 TABLE 35 GCC COUNTRIES: GENE SILENCING THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 112 TABLE 36 CELL REPLACEMENT THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 113 TABLE 37 NORTH AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 114 TABLE 38 EUROPE: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 114 TABLE 39 ASIA PACIFIC: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 115 TABLE 40 LATIN AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 115 TABLE 41 MIDDLE EAST: CELL REPLACEMENT THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 115 TABLE 42 GCC COUNTRIES: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 116 TABLE 43 GENE AUGMENTATION THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 117 TABLE 44 NORTH AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 117 TABLE 45 EUROPE: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 118 TABLE 46 ASIA PACIFIC: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 118 TABLE 47 LATIN AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 119 TABLE 48 MIDDLE EAST: GENE AUGMENTATION THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 119 TABLE 49 GCC COUNTRIES: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 119 TABLE 50 OTHER GENE THERAPIES MARKET, BY REGION, 2022–2032 (USD MILLION) 120 TABLE 51 NORTH AMERICA: OTHER GENE THERAPIES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 121 TABLE 52 EUROPE: OTHER GENE THERAPIES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 121 TABLE 53 ASIA PACIFIC: OTHER GENE THERAPIES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 122 TABLE 54 LATIN AMERICA: OTHER GENE THERAPIES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 122 TABLE 55 MIDDLE EAST: OTHER GENE THERAPIES MARKET, BY REGION, 2022–2032 (USD MILLION) 122 TABLE 56 GCC COUNTRIES: OTHER GENE THERAPIES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 123 TABLE 57 GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 125 TABLE 58 VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 126 TABLE 59 VIRAL VECTOR-BASED GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 126 TABLE 60 NORTH AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 126 TABLE 61 EUROPE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 127 TABLE 62 ASIA PACIFIC: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 127 TABLE 63 LATIN AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 128 TABLE 64 MIDDLE EAST: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 128 TABLE 65 GCC COUNTRIES: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 128 TABLE 66 RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 129 TABLE 67 RETROVIRAL VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 129 TABLE 68 NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 130 TABLE 69 EUROPE: RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 130 TABLE 70 ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 131 TABLE 71 LATIN AMERICA: RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 131 TABLE 72 MIDDLE EAST: RETROVIRAL VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 131 TABLE 73 GCC COUNTRIES: RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 132 TABLE 74 GAMMA RETROVIRAL VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 132 TABLE 75 NORTH AMERICA: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 133 TABLE 76 EUROPE: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 133 TABLE 77 ASIA PACIFIC: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 134 TABLE 78 LATIN AMERICA: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 134 TABLE 79 MIDDLE EAST: GAMMA RETROVIRAL VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 134 TABLE 80 GCC COUNTRIES: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 135 TABLE 81 LENTIVIRAL VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 136 TABLE 82 NORTH AMERICA: LENTIVIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 136 TABLE 83 EUROPE: LENTIVIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 136 TABLE 84 ASIA PACIFIC: LENTIVIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 137 TABLE 85 LATIN AMERICA: LENTIVIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 137 TABLE 86 MIDDLE EAST: LENTIVIRAL VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 137 TABLE 87 GCC COUNTRIES: LENTIVIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 138 TABLE 88 AAV VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 138 TABLE 89 NORTH AMERICA: AAV VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 139 TABLE 90 EUROPE: AAV VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 139 TABLE 91 ASIA PACIFIC: AAV VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 140 TABLE 92 LATIN AMERICA: AAV VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 140 TABLE 93 MIDDLE EAST: AAV VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 140 TABLE 94 GCC COUNTRIES: AAV VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 141 TABLE 95 OTHER VIRAL VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 141 TABLE 96 NORTH AMERICA: OTHER VIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 142 TABLE 97 EUROPE: OTHER VIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 142 TABLE 98 ASIA PACIFIC: OTHER VIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 143 TABLE 99 LATIN AMERICA: OTHER VIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 143 TABLE 100 MIDDLE EAST: OTHER VIRAL VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 143 TABLE 101 GCC COUNTRIES: OTHER VIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 144 TABLE 102 NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 144 TABLE 103 NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 145 TABLE 104 NORTH AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 145 TABLE 105 EUROPE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 146 TABLE 106 ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 146 TABLE 107 LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 147 TABLE 108 MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 147 TABLE 109 GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 147 TABLE 110 OLIGONUCLEOTIDE VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 148 TABLE 111 NORTH AMERICA: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 148 TABLE 112 EUROPE: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 149 TABLE 113 ASIA PACIFIC: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 149 TABLE 114 LATIN AMERICA: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 150 TABLE 115 MIDDLE EAST: OLIGONUCLEOTIDE VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 150 TABLE 116 GCC COUNTRIES: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 150 TABLE 117 OTHER NON-VIRAL VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 151 TABLE 118 NORTH AMERICA: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 151 TABLE 119 EUROPE: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 152 TABLE 120 ASIA PACIFIC: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 152 TABLE 121 LATIN AMERICA: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 153 TABLE 122 MIDDLE EAST: OTHER NON-VIRAL VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 153 TABLE 123 GCC COUNTRIES: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 153 TABLE 124 GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 155 TABLE 125 DEFICIENCY GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 156 TABLE 126 NORTH AMERICA: DEFICIENCY GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 156 TABLE 127 EUROPE: DEFICIENCY GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 157 TABLE 128 ASIA PACIFIC: DEFICIENCY GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 157 TABLE 129 LATIN AMERICA: GENE THERAPY MARKET FOR DEFICIENCY GENES, BY COUNTRY, 2022–2032 (USD MILLION) 158 TABLE 130 MIDDLE EAST: GENE THERAPY MARKET FOR DEFICIENCY GENES, BY REGION, 2022–2032 (USD MILLION) 158 TABLE 131 GCC COUNTRIES: GENE THERAPY MARKET FOR DEFICIENCY GENES, BY COUNTRY, 2022–2032 (USD MILLION) 158 TABLE 132 RECEPTOR GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 159 TABLE 133 NORTH AMERICA: RECEPTOR GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 159 TABLE 134 EUROPE: RECEPTOR GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 160 TABLE 135 ASIA PACIFIC: RECEPTOR GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 160 TABLE 136 LATIN AMERICA: RECEPTOR GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 161 TABLE 137 MIDDLE EAST: RECEPTOR GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 161 TABLE 138 GCC COUNTRIES: RECEPTOR GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 161 TABLE 139 ANTIGEN GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 162 TABLE 140 NORTH AMERICA: ANTIGEN GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 163 TABLE 141 EUROPE: ANTIGEN GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 163 TABLE 142 ASIA PACIFIC: ANTIGEN GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 164 TABLE 143 LATIN AMERICA: ANTIGEN GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 164 TABLE 144 MIDDLE EAST: ANTIGEN GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 164 TABLE 145 GCC COUNTRIES: ANTIGEN GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 165 TABLE 146 CYTOKINE GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 166 TABLE 147 NORTH AMERICA: CYTOKINE GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 166 TABLE 148 EUROPE: CYTOKINE GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 167 TABLE 149 ASIA PACIFIC: CYTOKINE GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 167 TABLE 150 LATIN AMERICA: CYTOKINE GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 168 TABLE 151 MIDDLE EAST: CYTOKINE GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 168 TABLE 152 GCC COUNTRIES: CYTOKINE GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 168 TABLE 153 TUMOR SUPPRESSOR GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 169 TABLE 154 NORTH AMERICA: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 170 TABLE 155 EUROPE: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 170 TABLE 156 ASIA PACIFIC: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 171 TABLE 157 LATIN AMERICA: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 171 TABLE 158 MIDDLE EAST: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 171 TABLE 159 GCC COUNTRIES: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 172 TABLE 160 GENE THERAPY MARKET FOR OTHER GENES, BY REGION, 2022–2032 (USD MILLION) 173 TABLE 161 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022–2032 (USD MILLION) 173 TABLE 162 EUROPE: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022–2032 (USD MILLION) 174 TABLE 163 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022–2032 (USD MILLION) 174 TABLE 164 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022–2032 (USD MILLION) 175 TABLE 165 MIDDLE EAST: GENE THERAPY MARKET FOR OTHER GENES, BY REGION, 2022–2032 (USD MILLION) 175 TABLE 166 GCC COUNTRIES: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022–2032 (USD MILLION) 175 TABLE 167 GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 177 TABLE 168 GENE THERAPY MARKET FOR NEUROLOGY, BY REGION, 2022–2032 (USD MILLION) 178 TABLE 169 NORTH AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 178 TABLE 170 EUROPE: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 179 TABLE 171 ASIA PACIFIC: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 179 TABLE 172 LATIN AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 180 TABLE 173 MIDDLE EAST: GENE THERAPY MARKET FOR NEUROLOGY, BY REGION, 2022–2032 (USD MILLION) 180 TABLE 174 GCC COUNTRIES: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 180 TABLE 175 GENE THERAPY MARKET FOR ONCOLOGY, BY REGION, 2022–2032 (USD MILLION) 181 TABLE 176 NORTH AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 182 TABLE 177 EUROPE: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 182 TABLE 178 ASIA PACIFIC: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 183 TABLE 179 LATIN AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 183 TABLE 180 MIDDLE EAST: GENE THERAPY MARKET FOR ONCOLOGY, BY REGION, 2022–2032 (USD MILLION) 183 TABLE 181 GCC COUNTRIES: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 184 TABLE 182 GENE THERAPY MARKET FOR HEMATOLOGY, BY REGION, 2022–2032 (USD MILLION) 185 TABLE 183 NORTH AMERICA: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 185 TABLE 184 EUROPE: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 186 TABLE 185 ASIA PACIFIC: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 186 TABLE 186 LATIN AMERICA: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 187 TABLE 187 MIDDLE EAST: GENE THERAPY MARKET FOR HEMATOLOGY, BY REGION, 2022–2032 (USD MILLION) 187 TABLE 188 GCC COUNTRIES: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 187 TABLE 189 GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2032 (USD MILLION) 188 TABLE 190 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2032 (USD MILLION) 188 TABLE 191 EUROPE: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2032 (USD MILLION) 189 TABLE 192 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2032 (USD MILLION) 189 TABLE 193 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2032 (USD MILLION) 190 TABLE 194 MIDDLE EAST: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2032 (USD MILLION) 190 TABLE 195 GCC COUNTRIES: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2032 (USD MILLION) 190 TABLE 196 GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 192 TABLE 197 IN VIVO GENE THERAPY: COMMERCIALIZED AND PIPELINE PRODUCTS 193 TABLE 198 IN VIVO GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 193 TABLE 199 NORTH AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 194 TABLE 200 EUROPE: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 194 TABLE 201 ASIA PACIFIC: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 195 TABLE 202 LATIN AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 195 TABLE 203 MIDDLE EAST: IN VIVO GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 195 TABLE 204 GCC COUNTRIES: IN VIVO GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 196 TABLE 205 EX VIVO GENE THERAPY: COMMERCIALIZED AND PIPELINE PRODUCTS 197 TABLE 206 EX VIVO GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 197 TABLE 207 NORTH AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 197 TABLE 208 EUROPE: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 198 TABLE 209 APAC: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 198 TABLE 210 LATIN AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 199 TABLE 211 MIDDLE EAST: EX VIVO GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 199 TABLE 212 GCC COUNTRIES: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 199 TABLE 213 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 201 TABLE 214 EXAMPLES OF INTRAVENOUSLY DELIVERED GENE THERAPY 201 TABLE 215 INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 202 TABLE 216 NORTH AMERICA: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 202 TABLE 217 EUROPE: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 203 TABLE 218 ASIA PACIFIC: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 203 TABLE 219 LATIN AMERICA: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 204 TABLE 220 MIDDLE EAST: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 204 TABLE 221 GCC COUNTRIES: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 204 TABLE 222 SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 205 TABLE 223 NORTH AMERICA: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 206 TABLE 224 EUROPE: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 206 TABLE 225 ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 207 TABLE 226 LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 207 TABLE 227 MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 207 TABLE 228 GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 208 TABLE 229 EXAMPLE OF GENE THERAPIES ADMINISTERED THROUGH OTHER ROUTES 208 TABLE 230 GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2032 (USD MILLION) 209 TABLE 231 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION) 209 TABLE 232 EUROPE: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION) 210 TABLE 233 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION) 210 TABLE 234 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION) 211 TABLE 235 MIDDLE EAST: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2032 (USD MILLION) 211 TABLE 236 GCC COUNTRIES: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION) 211 TABLE 237 GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 213 TABLE 238 GENE THERAPY MARKET FOR HOSPITALS, BY REGION, 2022–2032 (USD MILLION) 214 TABLE 239 NORTH AMERICA: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2032 (USD MILLION) 214 TABLE 240 EUROPE: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2032 (USD MILLION) 215 TABLE 241 ASIA PACIFIC: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2032 (USD MILLION) 215 TABLE 242 LATIN AMERICA: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2032 (USD MILLION) 216 TABLE 243 MIDDLE EAST: GENE THERAPY MARKET FOR HOSPITALS, BY REGION, 2022–2032 (USD MILLION) 216 TABLE 244 GCC COUNTRIES: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2032 (USD MILLION) 216 TABLE 245 GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY REGION, 2022–2032 (USD MILLION) 217 TABLE 246 NORTH AMERICA: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2032 (USD MILLION) 218 TABLE 247 EUROPE: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2032 (USD MILLION) 218 TABLE 248 ASIA PACIFIC: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2032 (USD MILLION) 219 TABLE 249 LATIN AMERICA: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2032 (USD MILLION) 219 TABLE 250 MIDDLE EAST: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY REGION, 2022–2032 (USD MILLION) 219 TABLE 251 GCC COUNTRIES: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2032 (USD MILLION) 220 TABLE 252 GENE THERAPY MARKET FOR OTHER END USERS, BY REGION, 2022–2032 (USD MILLION) 221 TABLE 253 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2032 (USD MILLION) 221 TABLE 254 EUROPE: GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2032 (USD MILLION) 222 TABLE 255 ASIA PACIFIC GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2032 (USD MILLION) 222 TABLE 256 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2032 (USD MILLION) 223 TABLE 257 MIDDLE EAST: GENE THERAPY MARKET FOR OTHER END USERS, BY REGION, 2022–2032 (USD MILLION) 223 TABLE 258 GCC COUNTRIES: GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2032 (USD MILLION) 223 TABLE 259 GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 225 TABLE 260 NORTH AMERICA: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET 226 TABLE 261 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 227 TABLE 262 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 228 TABLE 263 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 228 TABLE 264 NORTH AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 228 TABLE 265 NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 229 TABLE 266 NORTH AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 229 TABLE 267 NORTH AMERICA: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 229 TABLE 268 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 230 TABLE 269 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 230 TABLE 270 NORTH AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 230 TABLE 271 NORTH AMERICA: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 231 TABLE 272 US FDA APPROVALS FOR GENE THERAPY PRODUCTS, 2022–2024 232 TABLE 273 US: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 232 TABLE 274 US: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 233 TABLE 275 US: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 233 TABLE 276 US: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 233 TABLE 277 US: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 234 TABLE 278 US: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 234 TABLE 279 US: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 234 TABLE 280 US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 235 TABLE 281 US: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 235 TABLE 282 US: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 235 TABLE 283 CANADA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 236 TABLE 284 CANADA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 236 TABLE 285 CANADA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 237 TABLE 286 CANADA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 237 TABLE 287 CANADA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 237 TABLE 288 CANADA: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 238 TABLE 289 CANADA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 238 TABLE 290 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 238 TABLE 291 CANADA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 239 TABLE 292 CANADA: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 239 TABLE 293 EUROPE: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET 240 TABLE 294 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 242 TABLE 295 EUROPE: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 242 TABLE 296 EUROPE: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 242 TABLE 297 EUROPE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 243 TABLE 298 EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 243 TABLE 299 EUROPE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 243 TABLE 300 EUROPE: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 244 TABLE 301 EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 244 TABLE 302 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 244 TABLE 303 EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 245 TABLE 304 EUROPE: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 245 TABLE 305 GERMANY: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 246 TABLE 306 GERMANY: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 246 TABLE 307 GERMANY: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 246 TABLE 308 GERMANY: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 247 TABLE 309 GERMANY: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 247 TABLE 310 GERMANY: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 247 TABLE 311 GERMANY: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 248 TABLE 312 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 248 TABLE 313 GERMANY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 248 TABLE 314 GERMANY: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 249 TABLE 315 UK: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 249 TABLE 316 UK: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 250 TABLE 317 UK: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 250 TABLE 318 UK: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 250 TABLE 319 UK: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 251 TABLE 320 UK: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 251 TABLE 321 UK: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 251 TABLE 322 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 252 TABLE 323 UK: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 252 TABLE 324 UK: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 252 TABLE 325 FRANCE: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 253 TABLE 326 FRANCE: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 254 TABLE 327 FRANCE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 254 TABLE 328 FRANCE: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 254 TABLE 329 FRANCE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 255 TABLE 330 FRANCE: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 255 TABLE 331 FRANCE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 255 TABLE 332 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 256 TABLE 333 FRANCE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 256 TABLE 334 FRANCE: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 256 TABLE 335 ITALY: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 257 TABLE 336 ITALY: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 257 TABLE 337 ITALY: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 258 TABLE 338 ITALY: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 258 TABLE 339 ITALY: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 258 TABLE 340 ITALY: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 259 TABLE 341 ITALY: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 259 TABLE 342 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 259 TABLE 343 ITALY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 260 TABLE 344 ITALY: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 260 TABLE 345 SPAIN: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 261 TABLE 346 SPAIN: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 261 TABLE 347 SPAIN: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 261 TABLE 348 SPAIN: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 262 TABLE 349 SPAIN: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 262 TABLE 350 SPAIN: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 262 TABLE 351 SPAIN: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 263 TABLE 352 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 263 TABLE 353 SPAIN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 263 TABLE 354 SPAIN: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 264 TABLE 355 SWITZERLAND: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 264 TABLE 356 SWITZERLAND: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 265 TABLE 357 SWITZERLAND: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 265 TABLE 358 SWITZERLAND: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 265 TABLE 359 SWITZERLAND: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 266 TABLE 360 SWITZERLAND: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 266 TABLE 361 SWITZERLAND: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 266 TABLE 362 SWITZERLAND: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 267 TABLE 363 SWITZERLAND: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 267 TABLE 364 SWITZERLAND: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 267 TABLE 365 NETHERLANDS: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 268 TABLE 366 NETHERLANDS: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 268 TABLE 367 NETHERLANDS: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 269 TABLE 368 NETHERLANDS: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 269 TABLE 369 NETHERLANDS: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 269 TABLE 370 NETHERLANDS: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 270 TABLE 371 NETHERLANDS: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 270 TABLE 372 NETHERLANDS: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 270 TABLE 373 NETHERLANDS: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 271 TABLE 374 NETHERLANDS: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 271 TABLE 375 REST OF EUROPE: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 272 TABLE 376 REST OF EUROPE: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 272 TABLE 377 REST OF EUROPE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 272 TABLE 378 REST OF EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 273 TABLE 379 REST OF EUROPE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 273 TABLE 380 REST OF EUROPE: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 273 TABLE 381 REST OF EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 274 TABLE 382 REST OF EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 274 TABLE 383 REST OF EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 274 TABLE 384 REST OF EUROPE: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 275 TABLE 385 ASIA PACIFIC: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET 276 TABLE 386 ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 277 TABLE 387 ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 277 TABLE 388 ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 277 TABLE 389 ASIA PACIFIC: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 278 TABLE 390 ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 278 TABLE 391 ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 278 TABLE 392 ASIA PACIFIC: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 279 TABLE 393 ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 279 TABLE 394 ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 279 TABLE 395 ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 280 TABLE 396 ASIA PACIFIC: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 280 TABLE 397 CHINA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 281 TABLE 398 CHINA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 281 TABLE 399 CHINA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 281 TABLE 400 CHINA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 282 TABLE 401 CHINA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 282 TABLE 402 CHINA: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 282 TABLE 403 CHINA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 283 TABLE 404 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 283 TABLE 405 CHINA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 283 TABLE 406 CHINA: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 284 TABLE 407 JAPAN: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 285 TABLE 408 JAPAN: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 285 TABLE 409 JAPAN: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 285 TABLE 410 JAPAN: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 286 TABLE 411 JAPAN: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 286 TABLE 412 JAPAN: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 286 TABLE 413 JAPAN: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 287 TABLE 414 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 287 TABLE 415 JAPAN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 287 TABLE 416 JAPAN: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 288 TABLE 417 INDIA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 289 TABLE 418 INDIA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 289 TABLE 419 INDIA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 289 TABLE 420 INDIA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 290 TABLE 421 INDIA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 290 TABLE 422 INDIA: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 290 TABLE 423 INDIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 291 TABLE 424 INDIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 291 TABLE 425 INDIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 291 TABLE 426 INDIA: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 292 TABLE 427 AUSTRALIA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 292 TABLE 428 AUSTRALIA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 293 TABLE 429 AUSTRALIA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 293 TABLE 430 AUSTRALIA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 293 TABLE 431 AUSTRALIA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 294 TABLE 432 AUSTRALIA: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 294 TABLE 433 AUSTRALIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 294 TABLE 434 AUSTRALIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 295 TABLE 435 AUSTRALIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 295 TABLE 436 AUSTRALIA: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 295 TABLE 437 SOUTH KOREA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 296 TABLE 438 SOUTH KOREA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 296 TABLE 439 SOUTH KOREA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 297 TABLE 440 SOUTH KOREA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 297 TABLE 441 SOUTH KOREA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 297 TABLE 442 SOUTH KOREA: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 298 TABLE 443 SOUTH KOREA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 298 TABLE 444 SOUTH KOREA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 298 TABLE 445 SOUTH KOREA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 299 TABLE 446 SOUTH KOREA: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 299 TABLE 447 THAILAND: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 300 TABLE 448 THAILAND: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 300 TABLE 449 THAILAND: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 300 TABLE 450 THAILAND: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 301 TABLE 451 THAILAND: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 301 TABLE 452 THAILAND: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 301 TABLE 453 THAILAND: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 302 TABLE 454 THAILAND: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 302 TABLE 455 THAILAND: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 302 TABLE 456 THAILAND: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 303 TABLE 457 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 303 TABLE 458 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 304 TABLE 459 REST OF ASIA PACIFIC: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 304 TABLE 460 REST OF ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE 2022–2032 (USD MILLION) 304 TABLE 461 REST OF ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 305 TABLE 462 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 305 TABLE 463 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 305 TABLE 464 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 306 TABLE 465 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 306 TABLE 466 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 306 TABLE 467 LATIN AMERICA: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET 308 TABLE 468 LATIN AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 308 TABLE 469 LATIN AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 308 TABLE 470 LATIN AMERICA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 309 TABLE 471 LATIN AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 309 TABLE 472 LATIN AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 309 TABLE 473 LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 310 TABLE 474 LATIN AMERICA: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 310 TABLE 475 LATIN AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 310 TABLE 476 LATIN AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 311 TABLE 477 LATIN AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 311 TABLE 478 LATIN AMERICA: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 311 TABLE 479 BRAZIL: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 312 TABLE 480 BRAZIL: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 312 TABLE 481 BRAZIL: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 313 TABLE 482 BRAZIL: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 313 TABLE 483 BRAZIL: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 313 TABLE 484 BRAZIL: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 314 TABLE 485 BRAZIL: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 314 TABLE 486 BRAZIL: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 314 TABLE 487 BRAZIL: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 315 TABLE 488 BRAZIL: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 315 TABLE 489 MEXICO: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 316 TABLE 490 MEXICO: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 316 TABLE 491 MEXICO: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 316 TABLE 492 MEXICO: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 317 TABLE 493 MEXICO: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 317 TABLE 494 MEXICO: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 317 TABLE 495 MEXICO: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 318 TABLE 496 MEXICO: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 318 TABLE 497 MEXICO: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 318 TABLE 498 MEXICO: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 319 TABLE 499 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 319 TABLE 500 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 320 TABLE 501 REST OF LATIN AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 320 TABLE 502 REST OF LATIN AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 320 TABLE 503 REST OF LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 321 TABLE 504 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 321 TABLE 505 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 321 TABLE 506 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 322 TABLE 507 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 322 TABLE 508 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 322 TABLE 509 MIDDLE EAST: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET 324 TABLE 510 MIDDLE EAST: GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 324 TABLE 511 MIDDLE EAST: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 324 TABLE 512 MIDDLE EAST: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 325 TABLE 513 MIDDLE EAST: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 325 TABLE 514 MIDDLE EAST: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 325 TABLE 515 MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 326 TABLE 516 MIDDLE EAST: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 326 TABLE 517 MIDDLE EAST: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 326 TABLE 518 MIDDLE EAST: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 327 TABLE 519 MIDDLE EAST: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 327 TABLE 520 MIDDLE EAST: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 327 TABLE 521 GCC COUNTRIES: GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 328 TABLE 522 GCC COUNTRIES: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 328 TABLE 523 GCC COUNTRIES: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 329 TABLE 524 GCC COUNTRIES: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 329 TABLE 525 GCC COUNTRIES: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 329 TABLE 526 GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 330 TABLE 527 GCC COUNTRIES: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 330 TABLE 528 GCC COUNTRIES: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 330 TABLE 529 GCC COUNTRIES: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 331 TABLE 530 GCC COUNTRIES: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 331 TABLE 531 GCC COUNTRIES: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 331 TABLE 532 SAUDI ARABIA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 332 TABLE 533 SAUDI ARABIA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 333 TABLE 534 SAUDI ARABIA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 333 TABLE 535 SAUDI ARABIA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 333 TABLE 536 SAUDI ARABIA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 334 TABLE 537 SAUDI ARABIA: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 334 TABLE 538 SAUDI ARABIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 334 TABLE 539 SAUDI ARABIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 335 TABLE 540 SAUDI ARABIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 335 TABLE 541 SAUDI ARABIA: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 335 TABLE 542 UAE: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 336 TABLE 543 UAE: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 336 TABLE 544 UAE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 337 TABLE 545 UAE: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 337 TABLE 546 UAE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 337 TABLE 547 UAE: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 338 TABLE 548 UAE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 338 TABLE 549 UAE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 338 TABLE 550 UAE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 339 TABLE 551 UAE: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 339 TABLE 552 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 340 TABLE 553 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 340 TABLE 554 REST OF GCC COUNTRIES: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 340 TABLE 555 REST OF GCC COUNTRIES: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 341 TABLE 556 REST OF GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 341 TABLE 557 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 341 TABLE 558 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 342 TABLE 559 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 342 TABLE 560 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 342 TABLE 561 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 343 TABLE 562 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 343 TABLE 563 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 344 TABLE 564 REST OF MIDDLE EAST: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 344 TABLE 565 REST OF MIDDLE EAST: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 344 TABLE 566 REST OF MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 345 TABLE 567 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 345 TABLE 568 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 345 TABLE 569 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 346 TABLE 570 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 346 TABLE 571 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 346 TABLE 572 AFRICA: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET 348 TABLE 573 AFRICA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 348 TABLE 574 AFRICA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 349 TABLE 575 AFRICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 349 TABLE 576 AFRICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 349 TABLE 577 AFRICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 350 TABLE 578 AFRICA: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 350 TABLE 579 AFRICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 350 TABLE 580 AFRICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 351 TABLE 581 AFRICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 351 TABLE 582 AFRICA: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 351 TABLE 583 STRATEGIES DEPLOYED BY KEY COMPANIES IN GENE THERAPY MARKET 352 TABLE 584 GENE THERAPY MARKET: DEGREE OF COMPETITION 355 TABLE 585 GENE THERAPY MARKET: REGION FOOTPRINT 360 TABLE 586 GENE THERAPY MARKET: THERAPY TYPE FOOTPRINT 361 TABLE 587 GENE THERAPY MARKET: THERAPEUTIC AREA FOOTPRINT 362 TABLE 588 GENE THERAPY MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 363 TABLE 589 GENE THERAPY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 366 TABLE 590 GENE THERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 367 TABLE 591 GENE THERAPY MARKET: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2024 370 TABLE 592 GENE THERAPY MARKET: DEALS, JANUARY 2022–DECEMBER 2024 371 TABLE 593 GENE THERAPY MARKET: EXPANSIONS, JANUARY 2022–DECEMBER 2024 373 TABLE 594 BIOGEN: COMPANY OVERVIEW 374 TABLE 595 BIOGEN: PRODUCTS OFFERED 375 TABLE 596 BIOGEN: DEALS, JANUARY 2022–DECEMBER 2024 376 TABLE 597 NOVARTIS: COMPANY OVERVIEW 378 TABLE 598 NOVARTIS: PRODUCTS OFFERED 379 TABLE 599 NOVARTIS: DEALS, JANUARY 2022–DECEMBER 2024 380 TABLE 600 NOVARTIS: EXPANSIONS, JANUARY 2022–DECEMBER 2024 380 TABLE 601 NOVARTIS: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2024 381 TABLE 602 ALNYLAM PHARMACEUTICALS: COMPANY OVERVIEW 382 TABLE 603 ALNYLAM PHARMACEUTICALS: PRODUCTS OFFERED 383 TABLE 604 ALNYLAM PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2024 384 TABLE 605 ALNYLAM PHARMACEUTICALS: DEALS, JANUARY 2022–DECEMBER 2024 384 TABLE 606 ALNYLAM PHARMACEUTICALS: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2024 385 TABLE 607 SAREPTA THERAPEUTICS: COMPANY OVERVIEW 386 TABLE 608 SAREPTA THERAPEUTICS: PRODUCTS OFFERED 387 TABLE 609 SAREPTA THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2024 388 TABLE 610 SAREPTA THERAPEUTICS: DEALS, JANUARY 2022–DECEMBER 2024 388 TABLE 611 JAZZ PHARMACEUTICALS: COMPANY OVERVIEW 390 TABLE 612 JAZZ PHARMACEUTICALS: PRODUCTS OFFERED 391 TABLE 613 JAZZ PHARMACEUTICALS: EXPANSIONS, JANUARY 2022–DECEMBER 2024 392 TABLE 614 FERRING: COMPANY OVERVIEW 393 TABLE 615 FERRING: PRODUCTS OFFERED 394 TABLE 616 FERRING: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2024 394 TABLE 617 FERRING: DEALS, JANUARY 2022–DECEMBER 2024 394 TABLE 618 FERRING: EXPANSIONS, JANUARY 2022–DECEMBER 2024 395 TABLE 619 PFIZER: COMPANY OVERVIEW 396 TABLE 620 PFIZER: PRODUCTS OFFERED 397 TABLE 621 PFIZER: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2024 398 TABLE 622 PFIZER: DEALS, JANUARY 2022–DECEMBER 2024 398 TABLE 623 AMGEN: COMPANY OVERVIEW 399 TABLE 624 AMGEN: PRODUCTS OFFERED 400 TABLE 625 AMGEN: DEALS, JANUARY 2022–DECEMBER 2024 400 TABLE 626 AMGEN: EXPANSIONS, JANUARY 2022–DECEMBER 2024 400 TABLE 627 JOHNSON & JOHNSON SERVICES: COMPANY OVERVIEW 401 TABLE 628 JOHNSON & JOHNSON SERVICES: PRODUCTS OFFERED 402 TABLE 629 JOHNSON & JOHNSON SERVICES: DEALS, JANUARY 2022–DECEMBER 2024 402 TABLE 630 JOHNSON & JOHNSON SERVICES: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2024 403 TABLE 631 DAIICHI SANKYO COMPANY: COMPANY OVERVIEW 404 TABLE 632 DAIICHI SANKYO COMPANY: PRODUCTS OFFERED 405 TABLE 633 BIOMARIN PHARMACEUTICAL: COMPANY OVERVIEW 406 TABLE 634 BIOMARIN PHARMACEUTICAL: PRODUCTS OFFERED 407 TABLE 635 BIOMARIN PHARMACEUTICAL: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2024 407 TABLE 636 BIOMARIN PHARMACEUTICAL: EXPANSIONS, JANUARY 2022–DECEMBER 2024 408 TABLE 637 KYOWA KIRIN: COMPANY OVERVIEW 409 TABLE 638 KYOWA KIRIN: PRODUCTS OFFERED 410 TABLE 639 KYOWA KIRIN: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2024 411 TABLE 640 KYOWA KIRIN: DEALS, JANUARY 2022–DECEMBER 2024 411 TABLE 641 NIPPON SHINYAKU: COMPANY OVERVIEW 412 TABLE 642 NIPPON SHINYAKU: PRODUCTS OFFERED 413 TABLE 643 NIPPON SHINYAKU: DEALS, JANUARY 2022–DECEMBER 2024 414 TABLE 644 PTC THERAPEUTICS: COMPANY OVERVIEW 415 TABLE 645 PTC THERAPEUTICS: PRODUCTS OFFERED 416 TABLE 646 PTC THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2024 416 TABLE 647 UNIQURE: COMPANY OVERVIEW 417 TABLE 648 UNIQURE: PRODUCTS OFFERED 418 TABLE 649 UNIQURE: DEALS, JANUARY 2022–DECEMBER 2024 418 TABLE 650 JUVENTAS CELL THERAPY: COMPANY OVERVIEW 419 TABLE 651 CRISPR THERAPEUTICS: COMPANY OVERVIEW 419 TABLE 652 BLUEBIRD BIO: COMPANY OVERVIEW 420 TABLE 653 KRYSTAL BIOTECH: COMPANY OVERVIEW 421 TABLE 654 SHANGHAI SUNWAY BIOTECH: COMPANY OVERVIEW 421 TABLE 655 JW (CAYMAN) THERAPEUTICS: COMPANY OVERVIEW 422 TABLE 656 IASO BIOTECHNOLOGY: COMPANY OVERVIEW 422 TABLE 657 CARSGEN THERAPEUTICS HOLDINGS LIMITED: COMPANY OVERVIEW 423 TABLE 658 ADAPTIMMUNE: COMPANY OVERVIEW 423 TABLE 659 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW 424 TABLE 660 ULTRAGENYX PHARMACEUTICAL INC.: COMPANY OVERVIEW 424 FIGURE 1 GENE THERAPY MARKET SEGMENTATION & REGIONAL SCOPE 42 FIGURE 2 GENE THERAPY MARKET: YEARS CONSIDERED 44 FIGURE 3 RESEARCH DESIGN 46 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: GENE THERAPY MARKET 49 FIGURE 5 GENE THERAPY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023 51 FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023 52 FIGURE 7 ILLUSTRATIVE EXAMPLE OF NOVARTIS AG: REVENUE SHARE ANALYSIS (2023) 52 FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 53 FIGURE 9 GENE THERAPY MARKET: CAGR PROJECTIONS 55 FIGURE 10 DATA TRIANGULATION METHODOLOGY 57 FIGURE 11 GENE THERAPY MARKET, BY THERAPY TYPE, 2024 VS. 2032 (USD MILLION) 59 FIGURE 12 GENE THERAPY MARKET, BY VECTOR, 2024 VS. 2032 (USD MILLION) 60 FIGURE 13 GENE THERAPY MARKET, BY GENE TYPE, 2024 VS. 2032 (USD MILLION) 60 FIGURE 14 GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2024 VS. 2032 (USD MILLION) 61 FIGURE 15 GENE THERAPY MARKET, BY DELIVERY METHOD, 2024 VS. 2032 (USD MILLION) 61 FIGURE 16 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2024 62 FIGURE 17 GENE THERAPY MARKET, BY END USER, 2024 VS. 2032 (USD MILLION) 62 FIGURE 18 GEOGRAPHICAL SNAPSHOT OF GENE THERAPY MARKET 63 FIGURE 19 INCREASING INVESTMENTS IN GENE THERAPY RESEARCH—A KEY FACTOR DRIVING GROWTH 64 FIGURE 20 GENE SILENCING THERAPY ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2024 65 FIGURE 21 HOSPITALS TO DOMINATE END-USER MARKET TILL 2032 66 FIGURE 22 GERMANY TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 66 FIGURE 23 GENE THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 67 FIGURE 24 GENE THERAPY MARKET: VALUE CHAIN ANALYSIS 80 FIGURE 25 GENE THERAPY MARKET: SUPPLY CHAIN ANALYSIS 82 FIGURE 26 GENE THERAPY MARKET: ECOSYSTEM 82 FIGURE 27 PATENT ANALYSIS FOR GENE THERAPY MARKET, JANUARY 2014–DECEMBER 2024 86 FIGURE 28 AVERAGE SELLING PRICE TREND OF GENE THERAPIES, BY TYPE, 2022–2024 (USD) 96 FIGURE 29 AVERAGE SELLING PRICE OF GENE THERAPIES, BY REGION, 2023 (USD) 98 FIGURE 30 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 99 FIGURE 31 GENE THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 101 FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF GENE THERAPY PRODUCTS, BY DELIVERY METHOD 102 FIGURE 33 KEY BUYING CRITERIA FOR GENE THERAPY PRODUCTS, BY END USER 104 FIGURE 34 GENE THERAPY MARKET: INVESTMENT & FUNDING SCENARIO 105 FIGURE 35 NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT 227 FIGURE 36 NIH FUNDING, 2014–2024 231 FIGURE 37 EUROPE: GENE THERAPY MARKET SNAPSHOT 241 FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2023 (USD MILLION) 354 FIGURE 39 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023) 355 FIGURE 40 GENE THERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 358 FIGURE 41 GENE THERAPY MARKET: COMPANY FOOTPRINT 359 FIGURE 42 GENE THERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 365 FIGURE 43 EV/EBITDA OF KEY VENDORS 368 FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 368 FIGURE 45 GENE THERAPY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 369 FIGURE 46 BIOGEN: COMPANY SNAPSHOT (2023) 375 FIGURE 47 NOVARTIS: COMPANY SNAPSHOT (2023) 379 FIGURE 48 ALNYLAM PHARMACEUTICALS: COMPANY SNAPSHOT (2023) 383 FIGURE 49 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2023) 387 FIGURE 50 JAZZ PHARMACEUTICALS: COMPANY SNAPSHOT (2023) 391 FIGURE 51 FERRING: COMPANY SNAPSHOT (2023) 393 FIGURE 52 PFIZER: COMPANY SNAPSHOT (2023) 397 FIGURE 53 AMGEN: COMPANY SNAPSHOT (2023) 399 FIGURE 54 JOHNSON & JOHNSON SERVICES: COMPANY SNAPSHOT (2023) 402 FIGURE 55 DAIICHI SANKYO COMPANY: COMPANY SNAPSHOT (2023) 405 FIGURE 56 BIOMARIN PHARMACEUTICAL: COMPANY SNAPSHOT (2023) 406 FIGURE 57 KYOWA KIRIN: COMPANY SNAPSHOT (2023) 410 FIGURE 58 NIPPON SHINYAKU: COMPANY SNAPSHOT (2023) 413 FIGURE 59 PTC THERAPEUTICS: COMPANY SNAPSHOT (2023) 415 FIGURE 60 UNIQURE: COMPANY SNAPSHOT (2023) 417